Zobrazeno 1 - 10
of 56
pro vyhledávání: '"R A, Pomerantz"'
Publikováno v:
The British journal of dermatology. 163(5)
Microarray hybridization studies in Sézary syndrome (SS) have compared T lymphocytes from patients with cutaneous T-cell lymphoma with those of normal controls; a major limitation of this design is that significant inherent genetic variability of ly
Autor:
Z F Wann, Donald S. Burke, R S Pomerantz, Richard N. Miller, David N. Cowan, C A Carroll, Goldenbaum M, John F. Brundage
Publikováno v:
Journal of Infectious Diseases. 162:827-836
Since routine testing began, 677,463 members of the Reserve Components of the US Army have been tested for antibody to human immunodeficiency virus (HIV). Of these, 1063 were positive, for a crude prevalence of 1.57/1000 tested. Prevalence varied gre
Autor:
M, Mukhtar, R J, Pomerantz
Publikováno v:
IDrugs : the investigational drugs journal. 4(5)
The major focus of the Eighth Annual Retrovirus Conference was recent developments in the field of human retrovirology and related opportunistic infections at the forefront of clinical and scientific research. A number of state of the art lectures an
Publikováno v:
IDrugs : the investigational drugs journal. 4(10)
Autor:
R. J. Pomerantz
Publikováno v:
Cellular and molecular life sciences : CMLS. 60(10)
During the natural history of human immunodeficiency virus type I (HIV-1) infection, an impairment of interleukin-12 (IL-12) production precedes a switch from a T-helper 1 (Th1) to a T-helper 2 (Th2) stage of cellular immunity. Melatonin, the main ho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e142be2d90c9a3c3a41b672aff17a998
http://hdl.handle.net/11570/3130439
http://hdl.handle.net/11570/3130439
Autor:
F, Clavel, R J, Pomerantz
Publikováno v:
AIDS (London, England). 15
Autor:
R J, Pomerantz, H, Zhang
Publikováno v:
Current clinical topics in infectious diseases. 21
Publikováno v:
Current opinion in molecular therapeutics. 2(6)
Progenics's rCD4-IgG2 (PRO-542) is a recombinant fusion protein, which has been developed using the company's Universal Antiviral Binding (UnAB) technology, and is in phase I/II clinical trials for the treatment of human immunodeficiency virus type I
Autor:
R, Dornburg, R J, Pomerantz
Publikováno v:
Advances in pharmacology (San Diego, Calif.). 49